Letters to the Editor

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy

Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Haematologica Early view Feb 27, 2025 https://doi.org/10.3324/haematol.2024.286991